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3.3% in SMA2 and 1.8% in SMA3. In SMA2, FVC %pred. declined steeply 
from 5 to 15 years of age, followed by a levelling. Conversely, in SMA3 
patients FVC %pred. declined slower but steadily from 10 years of age. 
In SMA2 FVC% pred. significantly positively correlated with HFMS and 
RULM (r = 0.60, p < 0.01 and r = 0.55, p < 0.01) as in SMA3 (r = 0.7, p < 0.001 
and r = 0.6, p < 0.01). Recumbent length or ulnar length were used as surrogate 
for height in FVC %pred. calculation in SMA2. The results of this ongoing 
collaborative work suggested that in SMA2 and 3 lung volumes decline from 
age 5 and 10 respectively. Lung and motor function correlate well both in 
SMA2 and 3. This data will help the assessment of the long-term efficacy 
of treatment for SMA. 
http://dx.doi.org/10.1016/j.nmd.2019.06.337 
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Spinal muscular atrophy (SMA) is a genetic neuromuscular condition, 
caused by loss of SMN1 gene resulting in reduced SMN protein with 
degeneration of motor neurons in the anterior horn. In its most severe form 
(SMA type 1) children present with weakness before 6 months. Prior to 
the development of treatment, children never achieved the ability to sit, 
typically dying by age 2 years. Nusinersen, an antisense oligonucleotide, 
increases the production of SMN protein by the SMN2 gene, with improved 
motor function. SMA 1 children treated are living longer, attending nursery 
/ school. They are spending more time in an upright position (supported by 
wheelchairs / seating) as well as some achieving independent sitting and skills 
which were previously impossible. This study aims to evaluate the effect 
of improved function and sitting on their spines and management options. 
Routine assessment (with consent from families) of 30 SMA children on 
Nusinersen, aged 2 months to 9 years old, at Great Ormond Street Hospital 
commonly showed spinal asymmetry either at rest or when sat and was 
noted as young as 4 months in a patient. This necessitated provision of 
supportive thoraco-lumbar-sacral orthosis (TLSO) in over 70% of children 
with the aim to slow progression and need for spinal surgery. One child 
did not tolerate sitting therefore a TLSO has not been implemented and 
another was too severe for casting. TLSOs have further been used to help 
children practice sitting with more support. No deaths have been recorded 
in this SMA 1 group in the last 2 years, where previously they would have 
a palliative approach to their care with minimal physiotherapy input. This 
study shows the importance of early monitoring and proactive management 
of spinal asymmetries in children with SMA 1 on nusinersen. With this 
increasing population further consideration is needed to early and ongoing 
assessment of these patients. They need proactive physiotherapy management 
for new and developing challenges. 
http://dx.doi.org/10.1016/j.nmd.2019.06.338 
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Newborn screening (NBS) of spinal muscular atrophy (SMA) started in 
southern Belgium in March 2018. Initially covering the annual 17,000 births 
from the Liege Center, the program gradually expanded to 3 screening centres 
and currently covers 60,000 births per year. In NBS, turnaround time is 
critical. The aim of this report is to examine the effect of actions conducted 
to decrease it. During the first period, from March to December 2018 
(13,000 newborns), results were available within 15.35.0 days (meanSD) 
after birth. Dried blood spots (DBS) were delivered to the screening lab 
within 3.12.9 days, and analysis was performed within 83.5 days. Altogether, 
90% and 99% of results were available within 12.2 and 21.3 days after 
DBS reception, respectively. In order to decrease this delay, we conducted 
5 actions that were fully operational on January 01st. We developed and 
validated new primers for the qPCR method, in order to increase robustness 
and avoid repeating runs. We hired a full-time technician specifically devoted 
to the project and conducted a training of the whole screening staff in 
order to ascertain that out of office periods are always and fully covered. 
We purchased and commissioned a new qPCR device, only devoted to 
SMA screening We optimized the DNA extraction protocol, reducing the 
number of manual handling steps. We extended the neonatal screening 
program to whole Southern Belgium, with the addition of 40,000 sample/year 
from 2 other Brussels centers. DBS are punched in each lab and sent 
to Liege central lab, which allows having daily instead of weekly runs. 
These improvements led to a significant drop of 2 days (6.12.5) in the 
average time of results reporting. 90% and 99% of results are available 
within 9.3 and 11.6 days, respectively. Optimization and upscaling in the 
screening lab may thus significantly decrease screening delays. To further 
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Spinal muscular atrophy (SMA) is characterized by the degeneration of 
the cells of the anterior horn of the spinal cord, causing muscle weakness 
and progressive atrophy. Characterize the natural history of patients with 
SMA type II and III to obtain more information about the clinical course. 
Prospective observational study of patients with SMA II and III. Patients were 
evaluated every 6 months for a period of 3 years. We collected demographic, 
clinical and genetic data. For the clinical evaluation, 3 standardized scales 
of motor function were performed: Hammerrsmith Funtional Motor Scale 
Expanded (HFMSE), Upper Limb Module Revised (RULM), Sixt Minute 
Walking Test (6MWT) and Egen Klassifikation 2 (EK2). The patients were 
classified into different groups depending on the type of SMA. We have 
3 years follow-up in 19 patients SMA II and 5 patients SMA III and 2 
years follow-up in 32 patients SMA II and 14 patients SMA III. In SMA 
II patients, corrected for age, a significantly higher average score was found 
in the motor function scales in patients with SMA IIb. Similar results were 
found in patients with SMA III, with better values in patients IIIb. In 2 
years follow-up in SMA II patients younger than 6 years show an increase 
of + 1.5 in HFMSE and + 1.6 in RULM. In older than 6 years show a 
decrease of -2 in HFMSE and -0.9 in RULM. Motor function normalized 
by age is better in AME IIb than in AME IIa. Similarly, in AME IIIb than 
in AME IIIa. The age of AME II patients should be taken into account 
in the analysis of the response to new treatments. Patients younger than 6 
years show a different trajectory in the progression of the disease than older 
patients. 
http://dx.doi.org/10.1016/j.nmd.2019.06.340 
